GlaxoSmithKline Newswire

Comprehensive Real-Time News Feed for GlaxoSmithKline.

Results 1 - 20 of 6,409 in GlaxoSmithKline

  1. AstraZeneca investors revolt on pay as mega-mergers nearRead the original story w/Photo

    3 hrs ago | The Independent

    ... business." Mr Soriot said AstraZeneca was considering options similar to the asset swap between Novartis and GlaxoSmithKline earlier this week, in which the companies exchanged non-core units and formed a joint venture in consumer healthcare. He ...


  2. City Focus: Deals in the mix for pharmaceutical giantsRead the original story w/Photo

    5 hrs ago | Daily Mail

    ... Bill Ackman and his Canadian partner Valeant Pharmaceuticals. Closer to home, Britain's biggest drug-maker GlaxoSmithKline is seeking shareholder approval for a $16billion (A 9.5billion) asset swap with Novartis, exchanging cancer and vaccines units ...


  3. Sarepta's Still a Gamble, Even With FDA ReversalRead the original story

    5 hrs ago | The Motley Fool

    ... protein levels as a marker for clinical improvement. This originally came under scrutiny in studies of GlaxoSmithKline and Prosensa 's drisapersen. Some patients exhibited an increase in dystrophin but then clinically deteriorated, potentially ...


  4. Cell-Targeted Therapy Shows Early Promise Against MSRead the original story w/Photo

    5 hrs ago | WebMD

    ... is an "anti-B cell antibody" and is not yet approved for the treatment of MS. The research was funded by GlaxoSmithKline, the drug's maker. Researchers led by GlaxoSmithKline investigator Darrin Austin analyzed the effects of this drug compared to ...


  5. Study suggests targeting B cells may help with MSRead the original story

    7 hrs ago | PhysOrg Weblog

    ... dizziness, anxiety, fever, respiratory tract infection and nerve pain. Study author Daren Austin, PhD, of GlaxoSmithKline in Uxbridge, United Kingdom, and a member of the American Academy of Neurology, said the study results also suggest that ...


  6. Business briefs: Silicon Valley giants settle lawsuit over hiringRead the original story

    20 hrs ago | Star Tribune

    ... boards of both companies, comes amid a wave of health care and pharmaceutical deals. This week, Novartis and GlaxoSmithKline announced $20 billion in deals, and Valeant made a $45 billion hostile takeover bid for Allergan. It is also the latest ...


  7. The Revival of Cancer ImmunotherapyRead the original story

    Monday Apr 7 | Tech Review

    ... By blocking the activity of that protein, the antibody frees the immune cell to fight the disease. Roche , GlaxoSmithKline , Bristol-Myers Squibb , and others are also developing antibodies to release such brakes on the immune system. New details of ...


  8. Wandering ram to be auctioned in Durham CountyRead the original story

    Jan 10, 2014 | News Observer

    ... Sheriff’s Department and was spotted in the neighborhood near Streets at Southpoint mall and on the GlaxoSmithKline campus in Research Triangle Park. He was finally apprehended behind the closing door of a baited trap. Money from the auction ...


  9. Peter Adamson of GSK to Speak at 5th Ocular Diseases Conference Mar 21-22, 2013Read the original story

    Jan 17, 2013 | 24-7 Press Release

    Peter Adamson, Vice President and Head of Research and Ophthalmology at GlaxoSmithKline will give a featured presentation on "Lipoprotein-associated Phospholipase A2 Inhibition Regulates Retinal Vasopermeability During Experimental Diabetes" at GTCs 5th Ocular Diseases and Drug Development Conference to be held in San Francisco, CA on March 21-22, ... (more)


  10. The European Commission Moves to a Low-Carbon Economy Using Insulating Luxasolar Window FilmsRead the original story w/Photo

    May 24, 2011 | 24-7 Press Release

    ... W/m2K of double pane glazing to 1.6 W/m2K, and the 1.1 W/m2K of HR+ glazing to 0.97 W/m2K. At the site of GlaxoSmithKline in France the challenge was to obtain the most constant internal temperature, warm in winter and cool in summer, without any ...


  11. U.S. Stocks RiseRead the original story

    7 hrs ago | Wall Street Journal

    ... Square Capital Management and Valeant Pharmaceuticals disclosed an offer to buy Botox makerAllergan, and GlaxoSmithKline and Novartis announced a series of transactions, including Novartis' $14.5 billion purchase of Glaxo's oncology unit. swung ...


  12. Novartis Benefits a Bit More from Glaxo Partnership: KaloramaRead the original story

    8 hrs ago | PRWeb

    ... Kline. ( ). The two drug makers will cooperate and among other transactions, Glaxo will buy ...


  13. Novartis sees net profit jump 24 percentRead the original story

    8 hrs ago | The China Post

    ... strength," he said. He was referring to the unveiling of several multibillion-dollar deals with British GlaxoSmithKline and U.S. group Eli Lilly promising a major shake-up of the pharmaceutical sector. The string of takeovers and ventures by the ...


  14. Array Biopharma to report 3Q earnings April 29Read the original story

    9 hrs ago | The Boulder County Business Report

    ... call slides can be accessed on line here . Also, following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array reports that Novartis has indicated that it will ...


  15. Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the BoardRead the original story

    9 hrs ago | GlobeNewswire

    ... and CEO of Teva Pharmaceuticals Europe B.V. in 2012 and has previously held various senior positions in GlaxoSmithKline (GSK). Dr. van Odijk is also chairman of the board of Merus Biopharmaceuticals B.V. and member of the board of UDG Healthcare ...


  16. Baker Brothers notify of 4.99% shareholding in GalapagosRead the original story

    10 hrs ago | GlobeNewswire

    ... RA and in Phase 2 in Crohn's disease. Selective JAK1 inhibitor GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012) met the primary endpoint in a Phase 2 study in psoriasis. An exploratory Phase 1/2 study in ulcerative colitis is ...


  17. Sector movers: Healthcare stocks rise as M&A fever continuesRead the original story

    10 hrs ago | Live Charts

    ... players in the industries are beginning to spend. Pharmaceutical stocks were rising strongly again today. GlaxoSmithKline and Novartis unveiled a multi-billion dollar three-part deal on Tuesday, while AstraZeneca gained strongly on speculation that ...


  18. Swiss fund North Korean officer trainingRead the original story w/Photo

    11 hrs ago | Swissinfo

    ... helped lead the campaign to ban minarets in Switzerland. Another day, another big pharma deal. Novartis and GlaxoSmithKline (GSK) became the latest companies to join the industry's mergers and acquisition frenzy on Tuesday with a sweeping exchange ...


  19. This Big Pharma Just Went to the Dogs, and That's Great News for ShareholdersRead the original story w/Photo

    12 hrs ago | The Motley Fool

    ... Novartis announced a sweeping reform and refocusing of its operations via the $14.5 billion acquisition of GlaxoSmithKline 's oncology unit, the sale of its vaccine unit to Glaxo for $7.1 billion, and the sale of its animal health division to Eli ...


  20. Business this weekRead the original story

    13 hrs ago | The Economist

    ... in Allergan over recent months. See article Other notable deals included a three-part transaction between GlaxoSmithKline and Novartis , valued at around $20 billion, by which GSK is selling its cancer treatments to Novartis in return for its ...